Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform

The phase 3 NEURO-TTRansform trial showed eplontersen treatment for 65 weeks reduced transthyretin (TTR), halted progression of neuropathy impairment, and improved quality of life (QoL) in adult patients with hereditary TTR-mediated amyloidosis with polyneuropathy (ATTRv-PN), vs. historical placebo.

Bibliographic Details

Main Authors:	Conceição, Isabel (Author) , Berk, John L. (Author) , Weiler, Markus (Author) , Kowacs, Pedro A. (Author) , Dasgupta, Noel R. (Author) , Khella, Sami (Author) , Chao, Chi-Chao (Author) , Attarian, Shahram (Author) , Kwoh, T. Jesse (Author) , Jung, Shiangtung W. (Author) , Chen, Jersey (Author) , Viney, Nicholas J. (Author) , Yu, Rosie Z. (Author) , Gertz, Morie A. (Author) , Masri, Ahmad (Author) , Cruz, Márcia Waddington (Author) , Coelho, Teresa (Author)
Format:	Article (Journal)
Language:	English
Published:	13 August 2024
In:	Journal of neurology Year: 2024, Volume: 271, Issue: 10, Pages: 6655-6666
ISSN:	1432-1459
DOI:	10.1007/s00415-024-12616-6
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00415-024-12616-6
Author Notes:	Isabel Conceição, John L. Berk, Markus Weiler, Pedro A. Kowacs, Noel R. Dasgupta, Sami Khella, Chi-Chao Chao, Shahram Attarian, T. Jesse Kwoh, Shiangtung W. Jung, Jersey Chen, Nicholas J. Viney, Rosie Z. Yu, Morie Gertz, Ahmad Masri, Márcia Waddington Cruz, Teresa Coelho